Isothiafludine

异噻氟定

Report date: 2026/01/27 10:54:47
NME

Base Information

Drug NameIsothiafludine
Drug Alias NameNZ‐4W-28W-28-F
ClassificationNatural product/Extract
Mechanisms of ActionHepatitis B virus replication inhibitorsCapsid protein inhibitors
TargetsCapsid protein
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesShangHai HaiHe Biopharma Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Active IndicationsN/A
Inactive IndicationsHepatitis B, ChronicHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A